Microscopic disease at second-look laparotomy in advanced ovarian cancer
- 15 January 1985
- Vol. 55 (2) , 472-478
- https://doi.org/10.1002/1097-0142(19850115)55:2<472::aid-cncr2820550231>3.0.co;2-a
Abstract
During the 11-year interval from January 1971 to January 1982, 50 of 246 patients with advanced (Stage III and IV) epithelial ovarian carcinoma at second-look laparotomy had biopsy or cytologic evidence of persistent microscopic carcinoma. The stage and grade profile include 46 Stage III and 4 Stage IV patients: 4 borderline, 9 grade 1, 20 grade 2, and 17 grade 3 patients. Following second-look laparotomy, 4 patients received no further therapy, 45 received chemotherapy, and 1 received external radiation. No patient was lost to follow-up, and the median interval off therapy was 24 months. Progressive or recurrent disease has manifest in 12 (24%). No recurrences have developed either in patients younger than age 40 or in patients with grade 1 tumors. Two patients died of leukemia, 1 died of heart disease, and 35 (70%) are alive with no evidence of disease. In patients developing recurrence, the median progression-free interval was 17.5 months, with a range of 6 to 46 months. The median interval of survival following disease progression was 7 months. There was no evidence of progression at 2 years and 5 years in 81% and 70% of patients, respectively. The uncorrected 2- and 5-year survival rates were 96% and 71%, respectively. The 5-year survival rates for grades 1, 2, and 3 were 100%, 79%, and 36%, respectively. Other variables analyzed include number of positive foci, residual tumor volume at initial surgery, cytologic findings at second-look laparotomy, type of chemotherapy, and number of courses of chemotherapy before second-look laparotomy. In summary, patients with only microscopic evidence of disease at second-look surgery have a good probability for extended survival.This publication has 19 references indexed in Scilit:
- A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancerGynecologic Oncology, 1983
- Role of “third-look” laparotomy in the guidance of ovarian cancer treatmentGynecologic Oncology, 1983
- Surgically determined complete responders in advanced ovarian cancerGynecologic Oncology, 1983
- Second-look laparotomy in ovarian cancerGynecologic Oncology, 1982
- Second-look operations in the planned management of advanced ovarian carcinomaAmerican Journal of Obstetrics and Gynecology, 1982
- Second-look laparotomy in the management of gynecologic malignancyGynecologic Oncology, 1982
- Second-look laparotomy for ovarian cancerGynecologic Oncology, 1981
- CLASSIFICATION AND CHARACTERISTICS OF OVARIAN CANCERClinical Obstetrics and Gynecology, 1979
- Reexploration after treatment for ovarian carcinomaGynecologic Oncology, 1979
- Survival Curve for Cancer Patients Following TreatmentJournal of the American Statistical Association, 1952